Jo Morris

Dr. Jo Morris


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2016 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
RDRuth M Densham
Ruth M Densham
AGAlexander J Garvin
Alexander J Garvin
HSHelen R Stone
Helen R Stone
JSJoanna Strachan
Joanna Strachan
RBRobbie Baldock
Robbie Baldock
JMJo Morris
Jo Morris

1 October 2013 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
SESuzanne A Eccles
Suzanne A Eccles
EAEric Ofori Aboagye
Eric Ofori Aboagye
SASimak Ali
Simak Ali
AAAnnie S Anderson
Annie S Anderson
JAJo Armes
Jo Armes
ATAlastair M Thompson
Alastair M Thompson
Introduction: Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. Methods: More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer ‘stem’ cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. Results: The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. Conclusions: With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

21 August 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
LBLaura R Butler
Laura R Butler
RDRuth M Densham
Ruth M Densham
JJJunying Jia
Junying Jia
AGAlexander J Garvin
Alexander J Garvin
HSHelen R Stone
Helen R Stone
JMJo Morris
Jo Morris
The regulation of Ubiquitin (Ub) conjugates generated by the complex network of proteins that promote the mammalian DNA double‐strand break (DSB) response is not fully understood. We show here that the Ub protease POH1/rpn11/PSMD14 resident in the 19S proteasome regulatory particle is required for processing poly‐Ub formed in the DSB response. Proteasome activity is required to restrict tudor domain‐dependent 53BP1 accumulation at sites of DNA damage. This occurs both through antagonism of RNF8/RNF168‐mediated lysine 63‐linked poly‐Ub and through the promotion of JMJD2A retention on chromatin. Consistent with this role POH1 acts in opposition to RNF8/RNF168 to modulate end‐joining DNA repair. Additionally, POH1 acts independently of 53BP1 in homologous recombination repair to promote RAD51 loading. Accordingly, POH1‐deficient cells are sensitive to DNA damaging agents. These data demonstrate that proteasomal POH1 is a key de‐ubiquitinating enzyme that regulates ubiquitin conjugates generated in response to damage and that several aspects of the DSB response are regulated by the proteasome.

3 July 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MDManuel Daza-Martin
Manuel Daza-Martin
KSKatarzyna Starowicz
Katarzyna Starowicz
MJMohammed Jamshad
Mohammed Jamshad
STStephanie Tye
Stephanie Tye
GRGeorge E. Ronson
George E. Ronson
JMJo Morris
Jo Morris

17 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAnn Liza Piberger
Ann Liza Piberger
ABAkhil Bowry
Akhil Bowry
RKRichard D. W. Kelly
Richard D. W. Kelly
AWAlexandra K. Walker
Alexandra K. Walker
DGDaniel González-Acosta
Daniel González-Acosta
EPEva Petermann
Eva Petermann
Stalled replication forks can be restarted and repaired by RAD51-mediated homologous recombination (HR), but HR can also perform post-replicative repair after bypass of the obstacle. Bulky DNA adducts are important replication-blocking lesions, but it is unknown whether they activate HR at stalled forks or behind ongoing forks. Using mainly BPDE-DNA adducts as model lesions, we show that HR induced by bulky adducts in mammalian cells predominantly occurs at post-replicative gaps formed by the DNA/RNA primase PrimPol. RAD51 recruitment under these conditions does not result from fork stalling, but rather occurs at gaps formed by PrimPol re-priming and resection by MRE11 and EXO1. In contrast, RAD51 loading at double-strand breaks does not require PrimPol. At bulky adducts, PrimPol promotes sister chromatid exchange and genetic recombination. Our data support that HR at bulky adducts in mammalian cells involves post-replicative gap repair and define a role for PrimPol in HR-mediated DNA damage tolerance.

10 September 2013 in EMBO Reports
Verified
Journal Article
Open access
PDF file
AGAlexander J Garvin
Alexander J Garvin
RDRuth M Densham
Ruth M Densham
SBSarah A Blair‐Reid
Sarah A Blair‐Reid
KPKenny M Pratt
Kenny M Pratt
HSHelen R Stone
Helen R Stone
JMJo Morris
Jo Morris
SUMO conjugation is known to occur in response to double‐stranded DNA breaks in mammalian cells, but whether SUMO deconjugation has a role remains unclear. Here, we show that the SUMO/Sentrin/Smt3‐specific peptidase, SENP7, interacts with the chromatin repressive KRAB‐associated protein 1 (KAP1) through heterochromatin protein 1 alpha (HP1α). SENP7 promotes the removal of SUMO2/3 from KAP1 and regulates the interaction of the chromatin remodeler CHD3 with chromatin. Consequently, in the presence of CHD3, SENP7 is required for chromatin relaxation in response to DNA damage, for homologous recombination repair and for cellular resistance to DNA‐damaging agents. Thus, deSUMOylation by SENP7 is required to promote a permissive chromatin environment for DNA repair.